Beamion LUNG-1 and the Unmet Need in HER2-Mutant NSCLC

In an interview with Targeted Oncology, Gerrina Ruiter, MD, PhD, Netherlands Cancer Institute, discusses the contribution of the Beamion LUNG-1 study (NCT04886804) to addressing the unmet medical need in human epidermal growth factor receptor 2 (HER2)-mutant non–small cell lung cancer (NSCLC), a rare subtype of NSCLC in which half of patients develop brain metastases throughout their lifetime.¹

The Beamion LUNG-1 trial is a phase 1 trial evaluating zongertinib (Hernexeos) in advanced or metastatic HER2-mutant NSCLC, consisting of a dose-escalation phase and a dose-expansion phase. The dose-expansion phase, which involved 5 different cohorts, included 2 cohorts of patients with either treated or active untreated brain metastases. The results of this primary analysis, presented at the IASLC 2025 World Conference on Lung Cancer (WCLC), mark the first presentation of data including patients with brain metastases in this NSCLC subtype.

Read the full interview here.

REFERENCE:

1. Zhang Q, Yang Y, Xie M, et al. Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases. Lung Cancer. 2025;205:108616. doi:https://doi.org/10.1016/j.lungcan.2025.108616